News

Type Title Date
Press Release Ablative Solutions, Inc. Announces TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation
April 11, 2024
Read More
Press Release Ablative Solutions, Inc. Announces Primary Endpoint Met in the TARGET BP I Pivotal Trial of the Peregrine SystemTM Kit for Patients with Uncontrolled Hypertension
December 19, 2023
Read More
Press Release Ablative Solutions, Inc. Announces Enrollment Completion of TARGET BP I Study for Patients with Uncontrolled Hypertension
April 12, 2023
Read More
Press Release Ablative Solutions, Inc. Announces Completion of the Fourth Tranche of its Series D Preferred Financing Round for Unique Therapeutic Approach to Treating Uncontrolled Hypertension
June 13, 2022
Read More
Press Release Ablative Solutions Announces Publication of Data from the Peregrine Post-Market Study in the Journal of the American College of Cardiology: Cardiovascular Interventions
February 20, 2020
Read More
Press Release Ablative Solutions Announces Positive 12-Month Results from Study Evaluating Company’s Novel Therapy for Uncontrolled Hypertension
September 3, 2019
Read More
Press Release Ablative Solutions Announces Enrollment and Randomization of First Patient in Global Clinical Trial Evaluating Company’s Novel Therapy for Uncontrolled Hypertension
July 23, 2019
Read More
Press Release Ablative Solutions Announces Appointment of Kate Rumrill as President and Chief Executive Officer
July 11, 2019
Read More
Press Release Ablative Solutions Announces Results from Treatment of Patients with Hypertension in the European Peregrine Post-Market Study
March 7, 2019
Read More
Press Release Ablative Solutions, Inc. Announces $77 Million Financing for Unique Therapeutic Approach to Treating Uncontrolled Hypertension
January 3, 2019
Read More

Events

Type Title Location Start Date End Date